This study investigates the safety and effects of an investigational medication in patients with cancer who have not responded to certain cancer treatments. These treatments, known as anti-PD-1 or anti-PD-L1 therapies, are designed to help the immune system fight cancer. The study will focus on patients who either saw their disease progress or did not show significant improvement after 12 weeks of treatment.

Participants will receive the investigational medication and undergo various procedures to monitor the medication's effects on their cancer and overall health. The study will assess how the body processes the medication, known as pharmacokinetics, and its impact on tumors. Regular health checks and tests will be conducted to ensure participant safety.

• Who can participate: Adults who have been on anti-PD-1 or anti-PD-L1 therapy without significant improvement or with disease progression may participate. Key requirements include adequate organ function and a measurable lesion. Participants must not be currently responding to their existing therapy.
• Study details: Participants will take the investigational medication and attend regular study visits for health monitoring. A placebo, which is an inactive substance, will not be used in this study.